KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Work In Process (2019 - 2025)

Ionis Pharmaceuticals has reported Work In Process over the past 7 years, most recently at $8.7 million for Q1 2025.

  • Quarterly results put Work In Process at $8.7 million for Q1 2025, up 44.84% from a year ago — trailing twelve months through Mar 2025 was $8.7 million (up 44.84% YoY), and the annual figure for FY2024 was $6.7 million, up 21.95%.
  • Work In Process for Q1 2025 was $8.7 million at Ionis Pharmaceuticals, up from $6.7 million in the prior quarter.
  • Over the last five years, Work In Process for IONS hit a ceiling of $8.7 million in Q1 2025 and a floor of $954000.0 in Q2 2021.
  • Median Work In Process over the past 5 years was $3.9 million (2022), compared with a mean of $4.4 million.
  • Biggest five-year swings in Work In Process: tumbled 72.52% in 2021 and later soared 311.64% in 2022.
  • Ionis Pharmaceuticals' Work In Process stood at $5.8 million in 2021, then plummeted by 63.45% to $2.1 million in 2022, then surged by 159.7% to $5.5 million in 2023, then rose by 21.95% to $6.7 million in 2024, then soared by 30.92% to $8.7 million in 2025.
  • The last three reported values for Work In Process were $8.7 million (Q1 2025), $6.7 million (Q4 2024), and $6.7 million (Q3 2024) per Business Quant data.